Literature DB >> 27091214

Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Dhanya Vijayakumar1, Joseph Jankovic2.   

Abstract

Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27091214     DOI: 10.1007/s40265-016-0568-1

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  65 in total

1.  Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study.

Authors:  Cecilia Adrianzén; Cesar Arango-Dávila; Danilo Martínez Araujo; Ignacio Ruíz; Richard J Walton; Martin Dossenbach; Jamie Karagianis
Journal:  Hum Psychopharmacol       Date:  2010-08       Impact factor: 1.672

2.  Botulinum toxin as a treatment for tardive dyskinesia.

Authors:  Peter N van Harten; Ad Hovestadt
Journal:  Mov Disord       Date:  2006-08       Impact factor: 10.338

3.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.

Authors:  Wu-Fang Zhang; Yun-Long Tan; Xiang-Yang Zhang; Raymond C K Chan; Hao-Ran Wu; Dong-Feng Zhou
Journal:  J Clin Psychiatry       Date:  2010-09-21       Impact factor: 4.384

Review 6.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

7.  Botulinum toxin in painful tardive dyskinesia.

Authors:  Lorena Tschopp; Zulema Salazar; Federico Micheli
Journal:  Clin Neuropharmacol       Date:  2009 May-Jun       Impact factor: 1.592

Review 8.  Tardive dyskinesia syndromes: current concepts.

Authors:  Camila Catherine H Aquino; Anthony E Lang
Journal:  Parkinsonism Relat Disord       Date:  2014-01       Impact factor: 4.891

9.  A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation.

Authors:  Z Kefalopoulou; A Paschali; E Markaki; P Vassilakos; J Ellul; C Constantoyannis
Journal:  Acta Neurol Scand       Date:  2008-10-25       Impact factor: 3.209

10.  Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases.

Authors:  Vivienne Shen; Kathleen Clarence-Smith; Christine Hunter; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-10-22
View more
  15 in total

1.  Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.

Authors:  John M Kane; Christoph U Correll; Grace S Liang; Joshua Burke; Christopher F O'Brien
Journal:  Psychopharmacol Bull       Date:  2017-08-01

2.  Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.

Authors:  Richard C Josiassen; John M Kane; Grace S Liang; Joshua Burke; Christopher F O'Brien
Journal:  Psychopharmacol Bull       Date:  2017-08-01

3.  Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.

Authors:  Christoph U Correll; Richard C Josiassen; Grace S Liang; Joshua Burke; Christopher F O'Brien
Journal:  Psychopharmacol Bull       Date:  2017-08-01

4.  Functional (psychogenic) stereotypies.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  J Neurol       Date:  2017-06-26       Impact factor: 4.849

Review 5.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 6.  An Update on the Treatment of Chorea.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Curr Treat Options Neurol       Date:  2018-09-25       Impact factor: 3.598

7.  Movement disorders and chronic psychosis: Five new things.

Authors:  Davide Martino; Francesca Morgante
Journal:  Neurol Clin Pract       Date:  2017-04

8.  Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States.

Authors:  Natalie Bareis; Mark Olfson; Melanie Wall; T Scott Stroup
Journal:  Psychiatr Serv       Date:  2021-09-30       Impact factor: 4.157

9.  Deutetrabenazine in Tics Associated with Tourette Syndrome.

Authors:  Joseph Jankovic; Joohi Jimenez-Shahed; Cathy Budman; Barbara Coffey; Tanya Murphy; David Shprecher; David Stamler
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-11-07

10.  Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia?

Authors:  Jianbo Hu; Jianbo Lai; Shaohua Hu; Yi Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-31       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.